NuVasive, Inc. (NASDAQ:NUVA)

CAPS Rating: 5 out of 5

A medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders.

Results 1 - 20 of 32 : 1 2 Next »

Recs

0
Member Avatar s2dbaker (89.87) Submitted: 7/30/2014 11:38:10 PM : Outperform Start Price: $37.73 NUVA Score: -7.68

This stock will never go down again!!

Recs

0
Member Avatar TTime0917 (20.09) Submitted: 6/19/2014 8:22:48 AM : Outperform Start Price: $34.09 NUVA Score: +2.83

A good one to watch based on inside maneuvering.

Recs

0
Member Avatar troym72 (63.48) Submitted: 8/13/2013 2:31:02 PM : Outperform Start Price: $23.57 NUVA Score: +33.35

Taking a chance here that the recent earnings miss and the legal issue caused an over-reaction in share price. If (as the CEO say) they reach 1 billion in revenue in the next couple years, this could be a multi-bagger.

Recs

0
Member Avatar TerryHoodSr (49.06) Submitted: 7/29/2013 11:08:25 PM : Outperform Start Price: $22.80 NUVA Score: +38.21

growth

Recs

0
Member Avatar hammerpants (< 20) Submitted: 4/12/2013 1:12:20 AM : Outperform Start Price: $20.99 NUVA Score: +43.86

Great top line growth potential. New focus on bottom line. Will covert market share to big profits in due time.

Recs

0
Member Avatar mldottore (55.51) Submitted: 7/15/2012 11:19:33 PM : Outperform Start Price: $24.72 NUVA Score: -3.34

With an aging population growth in the medical device sector and in emerging markets will drive strong revenue growth.

Recs

0
Member Avatar RSue (88.23) Submitted: 5/1/2012 2:03:08 PM : Outperform Start Price: $15.02 NUVA Score: +99.92

This is a technological medical device company innovating at the forefront of minimally disruptive surgical products and procedures for the spine. With their surgical techniques and products, spine surgery patients have less blood loss, less time in hospital, and significantly quicker recovery time both initially after surgery and longer-term -- with patients typically going back to work within 4 - 6 weeks versus the more usual 6 months.

Recs

0
Member Avatar montgomeryil (< 20) Submitted: 1/17/2011 11:45:15 AM : Underperform Start Price: $27.95 NUVA Score: +27.14

While this stock appears to be solid on the fundamentals, the company in 2009 issued over 60 M new shares (thanks for the dilution without any dividends), and this January, it just gave away nearly - yes, at a $0 acquisition - 150,000 shares to its officers. These officers don't appear to care about the stock price either. Checking at Yahoo Finance shows that the company's officers exercised their stock options, then sold them time after time from July 2009 though the present. Looking at their long-term stock values, they had steadily increasing value from January 2006 until July of 2008. After that, the stock become very volatile, and it just so happens to coincide with greedy management exercising and selling off their options. Until the company starts either buying back its shares or paying a dividend, this Fool is not interested.

Recs

1
Member Avatar Acorn17 (93.61) Submitted: 11/17/2010 4:49:58 AM : Outperform Start Price: $24.73 NUVA Score: -23.36

This company is growing rapidly, has a strong market and a bright future. This is a bet that the pounding it just took is overdone. One BIG reservation that I have is the way that they give away stock options like candy at a Halloween party. Despite booking large losses in previous years they doled out multi-millions in stock based comp. This past quarter (Q3 2010) they wiped out half of net income with stock option related comp. Based on the pounding it's taken from the last earnings release (off over 45% from the highs) most options are now (fortunately for stockholders) underwater. I'm thinking about buying this one for real, but the way they treat their owners is giving me pause. Great product, great company, but waiting to see how they treat the owners. . .

Recs

1
Member Avatar whomonkyoulus (28.35) Submitted: 11/10/2010 3:47:50 AM : Outperform Start Price: $24.52 NUVA Score: -19.70

Oh whatever... They are still making 50 million/year and growing; that is a price/EBITDA of 20. The margin on sales is 85%. If they cannot find buyers here, then they surely will elsewhere.

Recs

1
Member Avatar 21popsontop (< 20) Submitted: 11/1/2010 4:17:19 PM : Outperform Start Price: $25.72 NUVA Score: -28.73

Longshots slipp'en and slid'en away,gett'en near over sold I do believe,only to see a better day the old fasion way . Did management say bankrupt,NO,not even close,but one would think so,as everyone flee's. One question? What day do they come back? Not sure,watch for the keys,but that they will indeed.

Recs

0
Member Avatar actionlogos (< 20) Submitted: 6/30/2010 7:10:13 PM : Outperform Start Price: $35.65 NUVA Score: -93.68

quality product, self marketing products, expanding into international markets.

Recs

0
Member Avatar FinanceGuy58 (57.47) Submitted: 12/13/2009 1:26:23 PM : Outperform Start Price: $28.43 NUVA Score: -58.33

Stock being hammered by short speculation and concerns over reimbursement. I think the concerns are overblown and this could be an easy double.

Recs

0
Member Avatar NUWildcat77 (< 20) Submitted: 10/30/2009 2:41:16 PM : Outperform Start Price: $35.36 NUVA Score: -92.13

Rapid revenue growth in minimally invasive spine surgery

Recs

0
Member Avatar pedromigz (23.58) Submitted: 9/14/2009 12:54:03 PM : Outperform Start Price: $41.99 NUVA Score: -106.79

pt47, z1

Recs

0
Member Avatar cyberccs (67.66) Submitted: 7/11/2009 2:35:04 AM : Outperform Start Price: $38.80 NUVA Score: -135.40

bull

Recs

0
Member Avatar power2macs (< 20) Submitted: 7/8/2009 3:33:38 AM : Outperform Start Price: $39.91 NUVA Score: -137.24

better tech and mkting force thans comps

Recs

0
Member Avatar monkeyking55 (< 20) Submitted: 11/17/2008 10:44:46 PM : Outperform Start Price: $39.71 NUVA Score: -150.75

As u can see in the stock trends, it is already higher then S&P 500 and it's going to keep outperforming S&P 500. Nuvasive has a product that everybody needs. Look at there sales and stock price in the past couples of yeear, they outperformed wall street prediction.

Recs

0
Member Avatar tableScraps (< 20) Submitted: 10/25/2008 6:14:33 AM : Outperform Start Price: $41.31 NUVA Score: -150.64

innovative product.

Recs

0
Member Avatar stockguy07 (< 20) Submitted: 9/2/2008 12:52:23 PM : Outperform Start Price: $48.50 NUVA Score: -87.72

TM

Results 1 - 20 of 32 : 1 2 Next »

Featured Broker Partners


Advertisement